Bristol Myers wrongfully denied exemption requests to COVID-19 vaccination policy, employees say in lawsuit CVS inks tech partnership with Microsoft to accelerate its 'digital-first' strategy Fore fires CEO Malik after SEC insider trading charges during his time as Immunomedics CFO Biden’s omicron battle plan includes private insurance reimbursement for at-home COVID tests Novartis CEO Narasimhan aims to surmount $9B patent cliff with 20 blockbuster launches Google rolls out new search tools for health information on Medicare services, languages spoken by providers Alpha challenger: Novartis pays UCB $150M to join Roche, AstraZeneca in Parkinson's race More growth on the way for CSL? Australian giant in talks to buy Vifor for $7.1B: report BD enters varicose vein treatment market with Venclose buy Acepodia snags $109M—and an early Zoom backer—to bankroll cell therapy for HER2-positive cancers Janssen taps Tempus' AI and real-world data library for cancer drug discovery Hospitals' infrequently published prices suggest substantial variance in radiology service charges to commercial payers Fast-growing Real Chemistry names new CEO to lead agency's digital transformation Featured Story | By Kevin Dunleavy In response to being told that they would be fired if they did not get vaccinated against COVID-19, four Bristol Myers Squibb employees have filed a lawsuit against the company claiming the drugmaker wrongfully denied their requests for religious exemptions. read more |
| |
|---|
|
| | The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more. |
Top Stories By Heather Landi CVS Health is tapping into Microsoft's technologies, including cloud computing, to accelerate its "digital-first" strategy. The pharmacy retail company announced Thursday a new strategic alliance with the tech giant focused on developing innovative solutions to provide more personalized care to consumers. read more By Kyle LaHucik The SEC charged former Immunomedics Chief Financial Officer Usama Malik with insider trading during his time at the biopharma, now owned by Gilead. As a result, Malik was fired as CEO and director of his current employer, Fore Biotherapeutics, where he lasted less than a year. read more By Andrea Park Nearly two years after the Trump administration tasked private health insurers with reimbursing the total costs of point-of-care COVID tests and health services, Biden will expand that requirement to include at-home tests, too. read more By Angus Liu Novartis is bracing for several losses of market exclusivity in the next five years, most notably for the company’s second-best-selling drug, Entresto. To hear CEO Vas Narasimhan tell it, the Swiss pharma is advancing more than enough programs to cushion the generics impact and drive growth in the long run, with or without acquisitions. read more By Rebecca Torrence Google is introducing new search features to make finding health information more accessible, addressing questions like whether a provider accepts Medicare or what languages that provider speaks, according to a Thursday blog post. read more By Nick Paul Taylor Novartis is betting $150 million on a rival to Parkinson’s disease drugs in development at companies including Roche and AstraZeneca. The deal sees Novartis commit to pay UCB up to around $1.5 billion in milestones for the chance to co-develop a midphase Parkinson’s prospect. read more By Kevin Dunleavy Australian biotech giant CSL is negotiating with Vifor Pharma to acquire the Swiss company for A$10 billion ($7.1 billion), says the Australian Financial Review. The acquisition would become the largest ever for CSL. read more By Conor Hale Venclose’s solution uses a radiofrequency ablation catheter threaded into the compromised vein to deliver heat and shrink the vessel. Once complete, the blood will naturally reroute its flow to nearby healthy veins. read more By Kyle LaHucik Acepodia is doubling down on its cancer cell therapy development with a $109 million series C round. The funding comes after a $47 million B round in March and multiple C-suite hires since then. Acepodia's lead asset is in a phase 1 trial in HER2-positive tumors. read more By Andrea Park Apparently not content to work toward improving cancer care from just one angle, Johnson & Johnson’s Janssen R&D unit and molecular data gatherer Tempus have expanded their partnership. read more By Dave Muoio A newly published analysis of hospitals' published imaging prices found limited compliance with CMS' price transparency rule as well as a stark range of hundreds or thousands of dollars between the prices they're charging Medicare and commercial payers. read more By Natalie Missakian Real Chemistry has been on a growth tear over the last two years, gobbling up smaller companies and adding hundreds of new hires. It also more than doubled its revenues, which are expected to approach the half-billion-dollar mark this year. Now it's getting a new top executive. read more | 